Add to Calendar 3/27/2019 8:15:00 AM 3/28/2019 2:30:00 PM 2019 Annual Meeting: State of Possible Conference
This year’s Annual Meeting is now the State of Possible Conference where we'll celebrate what’s possible in our industry and for patients today that wasn’t five or 10 years ago. The two-day event will draw over 600 industry leaders from Massachusetts and beyond to debate the most pressing challenges facing the life sciences to ensure we can continue this incredible success. Attendees will hear from the brightest minds through keynotes, panel discussions and 15-minute Possible Talks, inspiring and engaging content in the style of a TED Talk. We'll also have a networking reception, the State of Possible Celebration, immediately following Day 1 of the conference, where we'll have great food, drinks, a DJ. Attendees will also have access to the exhibits at the Museum of Science. Join us as we celebrate the State of Possible!
 

If you haven’t attended our Annual Meeting before, it is the premier east coast life sciences conference and this year’s event is better than ever. With speakers like Katrine Bosley, John Maraganore, Jeremy Levin, George Church, and more, we have some of the brightest names in biotech talking about the issues impacting our industry. See our incredible lineup of speakers and topics below. Online registration closes at noon on Tuesday, March 26th. Walk-in registrations will be available on-site. 

 Royal Sonesta Boston, 40 Edwin Land Blvd Cambridge MA 02142
Vice President, Health Economics and Outcomes Research, Alkermes
Amy K. O'Sullivan, Ph.D. is Vice President of Health Economics and Outcomes Research (HEOR) at Alkermes, Inc. O'Sullivan is a health economist with over 20 years of experience conducting health economics and outcomes research for the pharmaceutical industry. Over the course of her career, O'Sullivan has led the development and conduct of burden-of-illness studies, retrospective database analyses, patient-reported outcomes research, trial-based economic evaluations, and pharmacoeconomic models. Her research has been global in nature and spans a wide range of therapeutic areas including autoimmune conditions, cardiovascular disease, central nervous system/behavioral health disorders, metabolic disorders, musculoskeletal conditions, oncology, respiratory disease, women's health, and rare diseases. Prior to joining Alkermes, O'Sullivan held senior leadership positions at Vertex Pharmaceuticals, IMS Health, and OptumInsight, where she led research teams and provided scientific expertise on a range of outcomes research studies in support of product reimbursement in jurisdictions around the world. O'Sullivan has authored research studies published in Pharmacoeconomics, Value in Health, Managed Care, Journal of Medical Economics, International Journal of Technology Assessment in Health Care, and American Journal of Managed Care, among others. She has presented the results of her research at pharmacoeconomic and clinical congresses around the globe. O'Sullivan holds a BA in Economics and English from Boston College and Ph.D. in Health Economics from the Johns Hopkins University Bloomberg School of Public Health. She also holds an adjunct faculty position at the Boston University School of Public Health.

Brought to you by